LifeMD Shares Rise After Offering Lilly's GLP-1 Obesity Pill

Dow Jones04-21

By Elias Schisgall

Shares of LifeMD rose after the telehealth company said it is offering Eli Lilly's GLP-1 obesity pill, Foundayo, through its weight management program.

Shares were up 12% to $4.59 on Monday. The stock is up 35% this year.

LifeMD said eligible patients in its weight management program could receive Foundayo through the company's integration with LillyDirect, Eli Lilly's direct-to-consumer platform. Initial dosages begin at $149 a month.

"By working with LillyDirect, we are able to offer eligible patients streamlined access to this therapy at an accessible price point," Chief Executive Justin Schreiber said. "LifeMD remains dedicated to expanding access to high-quality, affordable weight management care, and the addition of Foundayo to our platform furthers that commitment."

LifeMD offers GLP-1 treatments from both Lilly and Novo Nordisk, the company said.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

April 20, 2026 12:15 ET (16:15 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629885727?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-21 00:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629885727","market":"us","top_or_hot":-1,"title":"LifeMD Shares Rise After Offering Lilly's GLP-1 Obesity Pill","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of LifeMD rose after the telehealth company said it is offering Eli Lilly's GLP-1 obesity pill, Foundayo, through its weight management program. \n</p>\n<p>\n  Shares were up 12% to $4.59 on Monday. The stock is up 35% this year. \n</p>\n<p>\n  LifeMD said eligible patients in its weight management program could receive Foundayo through the company's integration with LillyDirect, Eli Lilly's direct-to-consumer platform. Initial dosages begin at $149 a month. \n</p>\n<p>\n  \"By working with LillyDirect, we are able to offer eligible patients streamlined access to this therapy at an accessible price point,\" Chief Executive Justin Schreiber said. \"LifeMD remains dedicated to expanding access to high-quality, affordable weight management care, and the addition of Foundayo to our platform furthers that commitment.\" \n</p>\n<p>\n  LifeMD offers GLP-1 treatments from both Lilly and <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 20, 2026 12:15 ET (16:15 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LifeMD Shares Rise After Offering Lilly's GLP-1 Obesity Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLifeMD Shares Rise After Offering Lilly's GLP-1 Obesity Pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-21 00:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of LifeMD rose after the telehealth company said it is offering Eli Lilly's GLP-1 obesity pill, Foundayo, through its weight management program. \n</p>\n<p>\n  Shares were up 12% to $4.59 on Monday. The stock is up 35% this year. \n</p>\n<p>\n  LifeMD said eligible patients in its weight management program could receive Foundayo through the company's integration with LillyDirect, Eli Lilly's direct-to-consumer platform. Initial dosages begin at $149 a month. \n</p>\n<p>\n  \"By working with LillyDirect, we are able to offer eligible patients streamlined access to this therapy at an accessible price point,\" Chief Executive Justin Schreiber said. \"LifeMD remains dedicated to expanding access to high-quality, affordable weight management care, and the addition of Foundayo to our platform furthers that commitment.\" \n</p>\n<p>\n  LifeMD offers GLP-1 treatments from both Lilly and <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 20, 2026 12:15 ET (16:15 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4167","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629885727","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629885727","pubTimestamp":1776701700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of LifeMD rose after the telehealth company said it is offering Eli Lilly's GLP-1 obesity pill, Foundayo, through its weight management program.Shares were up 12% to $4.59 on Monday. The stock is up 35% this year.LifeMD said eligible patients in its weight management program could receive Foundayo through the company's integration with LillyDirect, Eli Lilly's direct-to-consumer platform. Initial dosages begin at $149 a month.\"By working with LillyDirect, we are able to offer eligible patients streamlined access to this therapy at an accessible price point,\" Chief Executive Justin Schreiber said. \"LifeMD remains dedicated to expanding access to high-quality, affordable weight management care, and the addition of Foundayo to our platform furthers that commitment.\". LifeMD offers GLP-1 treatments from both Lilly and Novo Nordisk, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4167":"医疗保健技术","BK4144":"石油与天然气的储存和运输","LFMD":"LifeMD Inc.","GLP":"Global Partners Lp","BK4183":"个人用品","BK4590":"PTP"},"translate_title":"LifeMD提供礼来公司GLP-1减肥药后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLP":1.5,"LFMD":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of LifeMD rose after the telehealth company said it is offering Eli Lilly's GLP-1 obesity pill, Foundayo, through its weight management program. \n\n\n  Shares were up 12% to $4.59 on Monday. The stock is up 35% this year. \n\n\n  LifeMD said eligible patients in its weight management program could receive Foundayo through the company's integration with LillyDirect, Eli Lilly's direct-to-consumer platform. Initial dosages begin at $149 a month. \n\n\n  \"By working with LillyDirect, we are able to offer eligible patients streamlined access to this therapy at an accessible price point,\" Chief Executive Justin Schreiber said. \"LifeMD remains dedicated to expanding access to high-quality, affordable weight management care, and the addition of Foundayo to our platform furthers that commitment.\" \n\n\n  LifeMD offers GLP-1 treatments from both Lilly and Novo Nordisk, the company said. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 20, 2026 12:15 ET (16:15 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629885727","isCrawlerRequest":true}